Zymeworks reported strong Q3 2026 results, surpassing revenue and EPS estimates, and subsequently raised its full-year revenue and Adjusted EBITDA guidance. The company also announced the completion of its acquisition of Theravance Biopharma and a new collaboration with Roche, indicating positive operational momentum and potential for future growth.
Zymeworks delivered a strong third quarter in 2026, beating analyst expectations for both revenue and EPS. This performance led to an upward revision of their full-year 2026 revenue and Adjusted EBITDA guidance, signaling robust operational health and positive future outlook. The completion of the Theravance Biopharma acquisition is expected to yield significant annual operating expense reductions, enhancing profitability. Furthermore, the new global collaboration with Roche for the ZW209 program provides a strong validation of Zymeworks' pipeline and potential for substantial future revenue streams. For traders, this presents a clear positive catalyst for ZYME in the short term due to the earnings beat and raised guidance, with long-term opportunities stemming from the strategic acquisition and collaboration. The key opportunity lies in the potential for continued pipeline success and cost synergies.